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Abstract Pregnancy Associated Breast Cancer (PABC) man-
ifests during pregnancy or within a year following delivery.
We sought to investigate differences in management, out-
come, clinical, histopathology and immunohistochemistry
(IHC) characteristics of PABC and matched controls in a
retrospective case control study. PABC and control patients
were selected from breast cancer cases of women ≤45 years,
diagnosed in the 2nd Department of Pathology, Semmelweis
University, Budapest, Hungary between 1998 and 2012.
Histopathology information on tumor type, grade, size, T, N,
lympho-vascular invasion (LVI), Nottingham Prognostic
Index (NPI), associated in situ lesions and IHC charcteristics:
ER, PgR, HER2, Ki67, p53 were recorded, IHC-based sub-
type was assessed, clinical, management and outcome data
were analysed. Thirty-one breast cancer cases were pregnancy
related. Clinical management data did not differ in cases and
controls. Histopathology of disease at presentation was not
significantly different, but NPI assessed the PABC group as
having poor, whereas controls as having intermediate progno-
sis. Associated in situ lesion was more often high grade
Extensive Intraductal Carcinoma Component (EIC) in
PABC. Triple negative and LuminalB prol tumors predomi-
nated in PABC. Disease-free and overall survival was inferior
compared to controls. PABC patients with LuminalB prol and
Triple negative tumors had inferior outcomes. On multivariate
analysis inferior prognosis of PABC was associated with
pregnancy. Our study has demonstrated inferior outcome of
PABC. Difference in tumor biology is reflected by the pre-
dominance of triple negative and LuminalB tumors in PABC.
The strength of the study is the analysis of complete pathology
and IHC data.
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Introduction
Pregnancy associated breast cancer (PABC) has been most
commonly defined as breast cancer complicating pregnancy,
manifesting during lactation or within 1 year after delivery.
The definition is not unanimous however, some authors define
the postpartum time frame from 6 months to 2 years after
delivery [1, 2].
Pregnancy has dual influence on breast cancer risk, it has
long-term protective effect but epidemiologic data also dem-
onstrate a transient increase in breast cancer incidence post-
partum. The postpartum time frame for this increased risk
ranges from 2 to 15 years, or even longer in case of older first
time pregnant women [3–5].
The incidence of PABC is estimated to be 1/10000 to
1/3000 pregnancies in Western countries, which is expected
to rise due to the trend of women postponing childbearing to
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later age. It is estimated that 10 % of breast cancer cases
affecting women ≤40 years of age are pregnancy related [6].
The situation is complicated at social, ethical, psychologi-
cal and medical levels, since the diagnosis is often challenging
due to physiologic changes occuring in the breast during
pregnancy or lactation, and because treatment of the pregnant
mother—however essential—can potentially harm the fetus.
Clinicians have very limited experience in this complex set-
ting, and this may lead to delayed diagnosis, delayed or under-
treatment of maternal breast cancer, controversial termination
of pregnancy or induced premature delivery.
The prognosis of PABC is more often reported as being
unfavorable [1, 7–10]. Whether this poor prognosis is related
to pregnancy or mainly due to the young age of patients—
which in itself is known to be a poor prognostic factor [11] - is
not clear.
Studies on PABC are rare, with only a few addressing
the pathological characteristics of the disease. The major-
ity supply information on the invasive tumor’s type, grade
and TNM stage, together with only the immunohisto-
chemistry (IHC) assessment of hormonal receptors (with
incomplete data provided by most of the studies); data on
Her2 status [12–19], Ki67 labeling index [12, 15, 17], p53
[12, 18], IHC-based tumor subtype [15] as well as on the
characteristics of eventual associated in situ lesions [19]
are scarce. To the best of our knowledge this is the first
matched case control study that combines information on
the management and outcome of PABC patients together
with analysis of all the relevant histopathology and IHC
information the pathologist can provide on the multidis-
ciplinary approach to PABC.
The aim of this retrospective matched case control study
was to investigate differences in clinicopathological features,
immunophenotype, treatment and outcome of PABC and
matched control, non-PABC cases.
Patients and Methods
First, upon specific approval of the Semmelweis University
Institutional Review Board (TUKEB 17/2006, 3/2013) we
reviewed the database of the 2nd Department of Pathology,
Semmelweis University and recorded all the breast cancer
cases of women ≤45 years of age, diagnosed between
J anua r y 1 s t , 1 998 and Novembe r 1 s t , 2 012 .
Histopathological data of the invasive tumor were obtained:
tumor type, Nottingham grade, multifocality, characteristics of
eventual associated in situ lesions, invasive tumor size, re-
gional lymph node involvement, TNM stage, Nottingham
Prognostic Index (NPI), presence of lympho-vascular inva-
sion (LVI), and the characteristics of IHC analysis were in-
vestigated: Estrogen receptor (ER), Progesterone receptor
(PgR) and Her2 expression, Ki67 labeling index and p53
expression. Used antibodies, methodology and FISH assess-
ment method are summarized in Supplementary Material 1.
ER and PgR statuses were evaluated according to the most
recent guidelines [20], Ki67 positivity was measured as the
ratio of positive tumor cell nuclei in the tumor and Her2 IHC
was evaluated according to current guidelines [21] by a 0–3
scale standard protocol. FISH results were evaluated accord-
ing to standard protocol [21]: non-amplified if the
HER2/CE17 ratio was less than 1.8, equivocal if this ratio
was between 1.8 and 2.2 and amplified if the HER2/CE17
ratio was over 2.2. When discordance occurred with Her2
IHC, FISH results were taken into consideration.
A tumor was considered ER and/or PgR positive if 10 % of
tumor cells demonstrated intranuclear positivity. In Ki67 IHC
assessment, a labeling index of 14 % or more was considered
high [22]. Based on IHC characteristics of the invasive tumor,
the IHC-based subtype was assessed. ER (and eventually
PgR) positive tumors with low Ki67 labeling index were
considered Luminal A (LumA), ER (and eventually PgR)
positive tumors with high Ki67 labeling index or HER2
expression were considered Luminal B subtype (LumBprol
or LumBHer2 respectively). The tumors which were hormone
receptor (HR) negative and expressed Her2 were considered
as Her2 positive, while tumors that did not express either HRs
or Her2 were considered as triple negative (TNBC). [23]
In the second step, we reviewed the patient database of
Semmelweis University for recorded breast cancer patients
and added all the available loco-regional and systemic treat-
ment information, relevant personal, parity and family history,
as well as data on eventual loco-regional and systemic re-
lapses. Finally, we selected all pregnancy associated breast
cancer cases manifesting during pregnancy, lactation or within
1 year after delivery.
Control patients were identified through the two databases,
each PABC patient was matched by age (±1 year) and year of
first breast cancer (BC) diagnosis (±1 year) to a control patient
with non-PABC.
Asymmetrical numeric data were analyzed by matched
Wilcoxon-test. Categorical data were compared using Chi-
square and Fisher’s exact test. Overall survival analyses were
performed using the Kaplan-Meier method. Overall survival
intervals were determined as the time period from initial
diagnosis to the time of death or date of last follow up.
Disease-free survival was calculated as the time interval from
initial breast cancer diagnosis to the date of disease recurrence
(loco-regional or systemic) or to time of death from BC, or to
the date of last follow-up if the patient was disease free.
Comparison between survival functions for different strata
was assessed with the log-rank statistic. Multivariate analysis
of prognostic factors was performed using Cox’s regression
model. Differences were considered significant when p≤0.05.
All statistical analyses were performed using Statistica 9.0
software (StatSoft Inc. Tulsa, OK).
L. Madaras et al.
Results
Clinical Data Analysis
Thirty-one breast cancer cases were found to be pregnancy
related, 10 manifesting during pregnancy and 21 during lac-
tation or postpartum period, within 1 year after delivery.
Patient characteristics and management data of all PABC
and control patients are summarized in Table 1. Median age
at diagnosis was 34 (range: 29–42) years for both the PABC
and control group (range: 28–42).
Treatment Modalities During Pregnancy
Among the pregnant patients three were diagnosed with breast
cancer during the first trimester, six during the second trimes-
ter and one in the third trimester of their pregnancy.
Six patients underwent surgery (four breast conserving
surgery/BCS/and two mastectomy, all with axillary lymph node
dissection/ALND/) while pregnant, followed by adjuvant thera-
py after delivery in four cases. One patient received neoadjuvant
chemotherapy (2xFAC) followed by surgery (mastectomy with
ALND) during pregnancy and adjuvant therapy after delivery.
One patient had surgery (BCS with ALND) followed by adju-
vant chemotherapy (6xFEC) while pregnant.
Pregnancy Outcome
One patient underwent induced abortion at 23rd week of
gestation, five patients had elective cesarean section (between
the 29th and 34th week of gestation) and four patients deliv-
ered their babies spontaneously (one preterm delivery).
Treatment Modality Comparison of PABC and Control Cases
There was no significant difference in the modality of surgery
(breast conserving surgery versus mastectomy) between cases
and controls. Axillary lymph node dissection was the main
therapy of choice in both groups. The pregnancy associated
group did not show significant difference in elapsed time
between diagnosis and surgery compared to controls (p=0.4,
data not shown). Neoadjuvant, adjuvant chemo- and radio-
therapy frequency or regimen did not differ (p=0.839) be-
tween the cases and controls. Adjuvant endocrine therapy was
Table 1 Patients characteristics and management data of PABC and control patients
PABC N=31 Control N=31 p-value
Age median (years) 34 34 match
Surgery Breast BCSa 12 (38.7 %) 14 (45.2 %) (BCSa vs other) 0.448m
mastectomyb 18 (58 %) 14 (45.2 %)
bilat mastectomyc 1 (3.2 %) 1 (3.2 %)
subcut mastectd 0 (0 %) 2 (6.5 %)
Axilla xe 1 (3.2 %) 1 (3.2 %) 1n
SNLBf 4 (12.9 %) 3 (9.7 %)
ALNDg 26 (83.9 %) 27 (87.1 %)
Oncological Treatment Neoadjh all 15 (48.4 %) 10 (32.3 %) 0.196m
followed by chemotx 11 (35.5 %) 6 (19.4 %) 0.342m
Chemotxi yes 24 (77.4 %) 24 (77.4 %) 0.605m
no 5 (16.1 %) 7 (22.6 %)
ndo 2 (6.5 %) 0 (0 %)
Regimenj antracyclin 6(19.4 %) 7(22.6 %) 0.839m
antracyclin + taxane 9(29 %) 9(29 %)
trastuzumab 4(12.9 %) 8(25.8 %)
other 5(16.1 %) 6(19.4 %)
ndo 4(12.9 %) 0(0 %)
Radiotxk yes 22 (70.9 %) 22 (70.9 %) 0.668m
no 7 (22.5 %) 9 (29 %)
ndo 2 (6.5 %) 0 (0 %)
Endocrl yes 12 (38.7 %) 24 (77.4 %) 0.004m
no 17 (54.8 %) 7 (22.6 %)
ndo 2 (6.5 %) 0 (0 %)
a Breast conserving surgery, bModified radical mastectomy, c Bilateral mastectomy, d Subcutaneous mastectomy, eNo surgery, f Sentinel lymph node
biopsy, g Axillary lymph node dissection, h Neoadjuvant chemotherapy, i Adjuvant chemotherapy, j Adjuvant chemotherapy regimen kAdjuvant
radiotherapy, l Adjuvant endocrine therapy, mChi-square test, n Fisher’s exact test, o No data
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however administered twice as frequently to controls (p=
0.004).
Relapse and Survival Comparison of PABC and Control
Patients
Table 2 summarizes relapse, survival and family history data
of PABC and controls.
Relapse was significantly more common in the PABC
group (p=0.003), 14 (45.2 %) patients had systemic relapse
as compared to three (9.7 %) control patients (p=0.0003).
Systemic relapse was the most common in LumBprol (6
patients out of 10) and triple negative cases (5 patients out
of 15); all these patients died of their disease. Disease free and
overall survival was significantly worse in PABC cases (p=
0.0004 and p=0.0007) (Fig. 1a and c). When survival data of
pregnant and postpartum patients were assessed separately,
the postpartum patient group showed significantly worse dis-
ease free (p=0.001) and overall survival (p=0.00008) as com-
pared with the controls. Disease free survival of pregnant
patients was inferior in comparison to control cases (p=
0.007), but overall survival was not significantly worse
(Fig. 1b and d). The outcome of PABC was inferior, since
thirteen PABC patients (41.9 %) died of the disease; 11 of
whom had postpartum breast cancer, while 2 patients (6.5 %)
died in the control group (p=0.005) (Fig. 2). There was no
difference between the PABC and non-PABC group when
overall and breast cancer related family history was evaluated.
Pathological Data Analysis
Table 3 summarizes the tumor characteristics of PABC and
control patients.
The most common tumor type was high grade invasive
ductal carcinoma (IDC) in both groups. There was no
significant difference in tumor T or N stage. For assess-
ment of median size of the invasive tumor, when patients
were treated with neoadjuvant chemotherapy, tumor size
before treatment was considered. Median size of PABC
was 24 mm (range 10–100 mm) compared to that of
con t r o l s (22 mm; range 9–85 mm, p= 0 .13 )
(Supplementary Material 2). The Notthingham Prognostic
Index (NPI) median value for PABC was 6 (range: 3.24–
8.5), and 4.65 (range: 3.24–7.2) for controls (Fig. 3). This
finding categorized PABC as a disease of poor prognosis,
while the non-PABC group was categorized as having
intermediate prognosis (p=0.03). Patients who had
complete or partial pathological response after neoad-
juvant chemotherapy were excluded from this analysis.
Table 2 Relapse, survival and
family history data of PABC and
control patients
a No data,
b Immunohistochemistry-based
subtype, c Triple negative
immunophenotype, d Breast can-
cer related family history, e Chi-
square test, f Fisher’s exact test
PABC Control p-value
N=31 N=31
Relapse yes 18 (58.1 %) 4 (12.9 %) 0.0003f
no 12 (38.7 %) 25 (80.6 %)
nda 1 (3.2 %) 2 (6.5 %)
Loco-regional yes 6 (19.4 %) 1 (3.2 %) 0.102f
no 24 (77.4 %) 28 (90.3 %)
nda 1 (3.2 %) 2 (6.5 %)
Systemic yes 14 (45.2 %) 3 (9.7 %) 0.003f
no 16 (51.6 %) 26 (83.9 %)
nda 1 (3.2 %) 2 (6.5 %)
Death Deceased 13 (41.9 %) 2 (6.5 %)
Alive All 18 (58.1 %) 29 (93.5 %) 0.005e
alive with disease 1 (3.2 %) 2 (6.5 %)
no evidence of disease 17 (54.8 %) 27 (87.1 %)
Death/IHC subtypeb LumA 0/0 0/5 See
Fig. 5LumBprol 6/10 0/8
LumBHer2 1/3 0/6
Her2+ 1/3 2/5
TNBCc 5/15 0/7
Family history All positive 14 (45.2 %) 15 (48.4 %) 0.558e
negative 7 (22.6 %) 5 (16.1 %)
nda 10 (32.3 %) 11 (35.5 %)
BC relatedd positive 8 (25.8 %) 7 (22.6 %) 0.837e
negative 13 (41.9 %) 13 (41.9 %)
nda 10 (32.3 %) 11 (35.5 %)
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Lympho-vascular invasion was detected in 61.3 % of
cases and 48.4 % of controls (p=0.228).
PABC and control cases were ER negative in 58 % and
38.8 %, respectively. The difference in PgR expression was
significant: 87.1 % of PABC cases, whereas 61.3 % of controls
did not express PgR (p=0.04). No significant difference was
noticed in Her2 status and by p53 immunostaining. All PABC
cases were highly proliferating byKi67 labeling index (p=0.01).
When analyzing IHC-based subtypes, triple negative tumors
predominated in PABC (48.4 %), followed by LumBprol tu-
mors (32.3 %). There were no LumA tumors in this group.
Associated in situ lesions showed significant differences in
patient cases and controls (p=0.017). In 45.2 % of PABC
cases, the invasive tumor was associated with high grade
Fig. 1 a Overall survival of PABC and control patients (p=0.0007). b
Overall survival of pregnant, postpartum and control patients (p=0.002)
(control vs. postpartum p=0.00008, control vs. pregnant p=0.203, post-
partum vs. pregnant p=0.049). c Disease free survival of PABC and
control patients (p=0.0004). dDisease free survival of pregnant, postpar-
tum and control patients (p=0.007) (control vs. postpartum p=0.001,
control vs. pregnant p=0.007, postpartum vs. pregnant p=0.979)
Fig. 2 a IHC-based subtype and
death of PABC and control
patients (n: number of patients). b
IHC-based subtype and death of
pregnant, postpartum and control
patients (n: number of patients)
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Table 3 Tumor characteristics of PABC and control cases
PABC Control p-value
N=31 N=31
Type IDCa 26 (83.9 %) 30 (96.8 %) 0.195p
Other 5 (16.1 %) 1 (3.2 %)
Associated in situ carcinoma none 11(35.5 %) 14(45.2 %) 0.017o
EIC non-highb 3(9.7 %) 3(9.7 %)
EIC highc 14(45.2 %) 3(9.7 %)
DCIS non-highd 1(3.2 %) 4(12.9 %)
DCIS highe 2(6.5 %) 7(22.6 %)
Multifocal disease No 24 (77.4 %) 28 (90.3 %) 0.306p
Yes 7 (22.6 %) 3 (9.7 %)
Grade 1 0 (0 %) 2 (6.5 %) 0.199o
2 5 (16.1 %) 8 (25.8 %)
3 26 (83.9 %) 21 (67.7 %)
T T1 6 (19.4 %) 8 (25.8 %) 0.522o
T2 9 (29 %) 12 (38.7 %)
T3 1 (3.2 %) 1 (3.2 %)
yT0 2 (6.5 %) 3 (9.7 %)
yT1 5 (16.3 %) 4 (12.9 %)
yT2 4 (12.9 %) 3 (9.7 %)
yT3 4 (12.9 %) 0 (0 %)
N Nx 1(3.2 %) 1(3.2 %) 0.646o
N0 6(19.4 %) 9(29 %)
N1 4(12.9 %) 7(22.6 %)
N2 4(12.9 %) 2(6.5 %)
N3 2(6.5 %) 2(6.5 %)
yN0 4(12.9 %) 5(16.1 %)
yN1 6(19.4 %) 4(12.9 %)
yN2 2(6.5 %) 1(3.2 %)
yN3 2(6.5 %) 0(0 %)
ER ER+ 13 (41.9 %) 19 (61.3 %) 0.127o
ER- 18 (58.1 %) 12 (38.7 %)
PgR PgR+ 4 (12.9 %) 12 (38.7 %) 0.04p
PgR- 27 (87.1 %) 19 (61.3 %)
ER + PgR+ 4 12 0.149p
ER + PgR- 9 7
Her2 Her2+ 6 (19.4 %) 11(35.5 %) 0.155o
Her2- 25(80.6 %) 20(64.5 %)
Ki67 high 31 (100 %) 24 (77.4 %) 0.01p
low 0 (0 %) 6 (19.4 %)
ndr 0 (0 %) 1 (3.2 %)
P53 positive 15 (48.4 %) 17 (54.8 %) 0.774o
negative 9 (29.3 %) 12 (38.8 %)
ndr 7 (22.6 %) 2 (6.5 %)
NPIf median (range) 6(3.24–8.5) 4.65(3.24–7.2) 0.03q
excellent (2–2.4)g 0 (0 %) 0(0 %) 0.172o
good(>2.4–3.4)h 2(6.5 %) 5(16.1 %)
intermed(>3.4–5.4)i 7(22.6 %) 12(38.8 %)
poor(>5.4)j 14(45.1 %) 9(29 %)
nak 8(25.8 %) 5(16.1 %)
LVIl no 10 (32.3 %) 15(48.4 %)
yes 19 (61.3 %) 15 (48.4 %) 0.228o
ndr 2 (6.5 %) 1 (3.2 %)
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extensive intraductal carcinoma component as compared with
9.7 % in controls. Forty-five percent of controls did not have
in situ carcinoma associated with the invasive tumor. The
predominant in situ lesion of controls was focal, high grade
ductal carcinoma in situ (22.6 %).
Upon multivariate Cox proportional model analysis
pregnancy related status was associated with both relapse
and survival, while age was associated with relapse
(Supplementary Material 3).
Discussion
As far as outcome of PABC is concerned data are conflicting:
some authors showed no difference in outcome of PABC and
non-PABC cases [14, 16, 24], while others consider PABC as
having unfavorable prognosis [1, 7–9]. In a recent meta-
analysis of 30 studies, Azim et al. found that PABC patients
had poor overall survival especially if breast cancer was
diagnosed within 1 year postpartum [25]. Our study also
demonstrates inferior outcome of PABC patients, systemic
relapse and death being significantly more common in
this group. Disease free survival of both pregnant and
postpartum patients was worse than that of controls, and
overall survival of the postpartum group was inferior com-
pared to that of controls.
Previous studies have addressed the hypothesis that the
unfavorable outcome of PABC is related to delayed diagnosis
resulting in advanced disease at presentation [2, 26].We found
no significant delay in surgery and initiation of oncological
treatment of PABC versus control patients, although we could
not assess the time elapsing between manifestation of first
symptoms and time of initial diagnosis. Disease at presenta-
tion (size, T, N) was not found to be significantly different
between the two groups; treatment modalities (surgery, neo-
adjuvant or adjuvant treatment frequency or regimen) did not
differ except for the frequency of endocrine therapy, which
was more common in the control group.
NPI is a continuous variable that combines several prog-
nostic factors of BC (grade, tumor size, number of metastatic
lymph nodes) [27, 28]. Although there was no significant
difference between PABC and non-PABC when tumor size,
T, N and grade at initial presentation were assessed separately,
the combination of these factors by NPI resulted in significant
difference: based on median NPI value the PABC group was
categorized as having poor prognosis, while the non-PABC
group as having intermediate prognosis. This finding suggests
differences in tumor aggressiveness, which can not be cap-
tured by individual assessment of classical histopathological
prognostic factors.
Progesterone receptor expression showed significant dif-
ference between PABC cases and controls, with PABC being
mainly PgR negative. Although there were more ER + PgR-
LuminalB tumors in PABC patients, the difference was not
statistically significant, thus the detected difference in PgR
expression is driven mainly by the over-representation of
triple negative tumors in PABC, since Her2 expression did
not show major differences.
Fig. 3 Nottingham Prognostic Index of PABC and control cases
(p=0.03, Wilcoxon)
Table 3 (continued)
PABC Control p-value
N=31 N=31
IHC-Subtypem LumA 0 (0 %) 5 (16.1 %) 0.015o
LumBprol 10 (32.3 %) 8 (25.8 %)
LumBHer2 3 (9.7 %) 6 (19.4 %)
Her2 3 (9.7 %) 5 (16.1 %)
TNBCn 15(48.4 %) 7 (22.6 %)
a Invasisve ductal carcinoma, b Extensive intraductal carcinoma component non-high nuclear grade, c Extensive intraductal carcinoma component high
nuclear grade, d Ductal carcinoma in situ non-high nuclear grade, e Ductal carcinoma in situ high nuclear grade, f Nottingham Prognostic Index,
g Excellent prognosis by NPI, h Good prognosis by NPI, i Intermediate prognosis by NPI, j Poor prognosis by NPI, k NPI not assessable- partial or
complete pathological response after neoadjuvant chemotherapy, l Lympho-vascular invasion, m Immunohistochemistry-based subtype, n Triple negative
immunophenotype,o Chi-square test, p Fisher’s exact test, qWilcoxon test, r No data
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Ki67 labeling index was above 15 % in all PABC cases,
reflected also by the difference in IHC-based tumor subtypes,
namely that there were no LumA tumors in this group. From
all PABC cases 48.4 % showed triple negative and 32.3 %
LumBprol phenotype. These two subtypes represented around
80 % of all PABC cases, while only 48 % of the control cases.
Our finding on the over-representation of TNBC in PABC is
in concordance with that of other authors [18]. Survival
assessed by IHC-based subtypes showed the worst survival
of patients with LumBprol and triple negative phenotype,
especially in postpartum cases. These findings underline the
importance of Ki67 testing in ER + Her2- tumors, in order to
detect tumors of LumBprol subtype with an eventual worse
prognosis.
Associated ductal in situ lesions are known to have an
impact on local control of breast cancer. There is a higher risk
of local recurrence if ductal carcinoma in situ demonstrates
high nuclear grade, comedo necrosis, is extensive, involves
surgical margins or the patient is young [29–31]. These factors
are not entirely unrelated though, since young patients
(≤45 years) tend to have high nuclear grade in situ lesions
with comedo necrosis and the extent of DCIS is significantly
greater compared to older women [29, 31].
In our study, PABC as comparedwith non-PABCwasmore
often associated with an extensive intraductal carcinoma com-
ponent showing high nuclear grade and comedo necrosis, but
there was no difference in local relapse. Our finding on the one
hand can underline the unfavorable biology of PABC, since
increasing molecular evidence suggest that high grade in situ
ductal lesions harbour complex and heterogeneous genomic
alterations that are highly similar to that of high grade IDC and
these aberrations are different from that of low grade DCIS
and IDC [32, 33]. On the other hand, this finding can also
incite thoughts about the significantly more extensive involve-
ment of ducts by high grade in situ lesions in PABC, which
might be a further consequence of the altered milieu related to
pregnancy and the postpartum condition.
Possible explanations for the detected outcome differences
between PABC and non-PABC besides different tumor biol-
ogy may involve the relative immunosuppressed state associ-
ated with pregnancy, the altered hormonal milieu (the placenta
and the fetus as new endocrine “organs”, higher estrogen,
progesterone and growth hormone levels during pregnancy,
increased prolactin level during lactation). Changes in tumor
microenvironment during pregnancy (increased responsive-
ness of the breast to growth factor stimulation) or during
postpartum remodeling—when extracellular matrix modifica-
tions associated with post-lactational involution create a mi-
lieu that resembles wound-healing [34] - are all known factors
enhancing tumor growth and metastasis. O’Brien et al. have
demonstrated the role of post-lactational involution-
associated, alternatively activated M2-type macrophages that
share characteristics with Tumor-associated macrophages
(TAMs). TAMs, by secreting growth factors, enhance tumor
growth. Immature macrophages might also suppress cytotoxic
T-cell function, thus creating an immunosuppressed microen-
vironment [35, 36]. Fornetti et al. have proposed a model
showing how post-lactational epithelial cells transition to be-
come phagocytic and engulf the apoptotic (formerly milk-
producing) cells during involution while secreting cytokines
and growth factors, thus resulting in a tumor-supportive mi-
croenvironment [34].
The weakness of our study is its retrospective nature and
the lack of information on the time elapsed between first
symptoms and first diagnosis of breast cancer. Its
strength is the combination of management data and
survival analysis with detailed histopathology and IHC
data analysis, including not only HR status, but Her2,
Ki67, p53, IHC-based subtype, NPI and associated in
situ lesion analysis as well. To the best of our knowl-
edge these factors have not been investigated so far
together in a matched case control study on PABC.
In conclusion, our study has demonstrated inferior outcome
of PABC, especially when detected postpartum. Unfavorable
tumor biology was reflected by the predominance of triple
negative and LumBprol tumors and PABC was commonly
associated with high grade EIC. To our best knowledge, this
latter finding has not been previously addressed. Individual
analysis of classical prognostic factors could not detect infe-
rior prognosis of PABC, but combination of these factors by
NPI has predicted the aggressive nature and poor prognosis of
pregnancy associated breast cancer. Based on the literary data,
it seems that besides tumor biology, the tumor microenviron-
ment altered by pregnancy and the postpartum state, most
probably also plays important role in the inferior outcome of
the disease. This issue is still underinvestigated though, new
treatments (e.g. successful targeting of tumor microenviron-
ment) howevermight contribute to improving the prognosis of
PABC.
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